Bynea

NEA AWARDS GRANTS FOR ECZEMA RESEARCH TO 13 INVESTIGATORS

Retrieved on: 
Tuesday, December 6, 2022
New York University, NIH, APRN, NEA, Human, Dermatitis, GA, Doctor of Philosophy, Patient, University of California, San Diego, Science, New York University Grossman School of Medicine, Research, Blueprint, MSN, Emory University School of Medicine, Disease, University of Texas at Austin, Quality of life, Caregiver, Multimedia, Pedrá, Seriousness, University, National Institutes of Health, Education, Inflammation, Bynea, Health, Atopic dermatitis, Pharmaceutical industry, Renewable energy, Management, Medicine, MD

NOVATO, Calif., Dec. 6, 2022 /PRNewswire/ -- The National Eczema Association (NEA) today announced the recipients for its 2022 research grants. From both U.S.-based and international applications, the research projects of 13 outstanding investigators were selected, representing grants totaling nearly $730,000. 2022 marked a significant jump in NEA's investment in innovative eczema research, from $515,000 in 2021, with a new award tier and an increase from nine to 13 recipients.

Key Points: 
  • From both U.S.-based and international applications, the research projects of 13 outstanding investigators were selected, representing grants totaling nearly $730,000.
  • The largest private nonprofit funder of eczema research, NEA has invested nearly $3 million since its first grant was awarded in 2004.
  • The 2022 research grants are awarded in categories as follows:
    Impact Research Grant Provides funding support for collaborative research projects to conduct multi-institution innovative eczema research.
  • Champion Research Grant Encourages proven researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

ECZEMAWISE RECOGNIZED WITH TWO TOP PRIZES FROM EHEALTHCARE LEADERSHIP AWARDS

Retrieved on: 
Thursday, November 10, 2022
Quality of life, Human, Health, Dermatitis, Adult, NEA, Research, Education, Mental health, Multimedia, News, Seriousness, App Store (iOS/iPadOS), Decision-making, Blueprint, Disease, Sleep, Bynea, Physician, Patient, Google Play, Caregiver, Health insurance

NOVATO, Calif., Nov. 10, 2022 /PRNewswire/ -- The National Eczema Association (NEA) announced today that it was presented with two top prizes from the eHealthcare Leadership Awards for its app, EczemaWise .

Key Points: 
  • NOVATO, Calif., Nov. 10, 2022 /PRNewswire/ -- The National Eczema Association (NEA) announced today that it was presented with two top prizes from the eHealthcare Leadership Awards for its app, EczemaWise .
  • EczemaWise received the highest-level Platinum prize in the categories of both Best Care/Disease Management and Best Mobile App.
  • NEA developed EczemaWise with input from the eczema community and physicians to help individuals manage their eczema and improve their quality of life.
  • In the eHealthcare Leadership Awards evaluation, one of the judges called EczemaWise "a great tool to improve overall health and wellness."

NEW RESEARCH FROM NEA FINDS SHARED DECISION MAKING BENEFICIAL IN CARE OF PATIENTS WITH ECZEMA

Retrieved on: 
Wednesday, July 6, 2022
Decision-making, Patient, Caregiver, Conditional sentence, Research, Behavior, Health, JAMA Dermatology, Oregon Health and Science University Center for Women's Health, Disease, Health care, Knight Cancer Institute, NEA, Perception, OHSU Center for Health & Healing, Biostatistics, Center, Doctor of Philosophy, Seriousness, Human, Blueprint, Dermatitis, Bynea, Dermatology, MD, Multimedia, Education, Oregon Health & Science University, Health insurance, Pharmaceutical industry, Medicine, Risk management, Online shopping

NOVATO, Calif., July 6, 2022 /PRNewswire/ -- The National Eczema Association (NEA) today announced the publication of its new research revealing the importance of shared decision making between patients and healthcare providers in the treatment of eczema.

Key Points: 
  • NOVATO, Calif., July 6, 2022 /PRNewswire/ -- The National Eczema Association (NEA) today announced the publication of its new research revealing the importance of shared decision making between patients and healthcare providers in the treatment of eczema.
  • The NEA research team set out to answer these questions with a survey of its eczema patient and caregiver community.
  • Upon further analysis, they also determined that "self-reported knowledge about the causes of eczema was associated with past and future shared decision making" and that "severity of the disease was inversely associated with past shared decision making behavior."
  • These findings confirm an important role for shared decision making for improving patient satisfaction with their care.

NEA IS AWARDED COMPETITIVE GRANT FROM PFIZER TO INVESTIGATE THE MEANING OF 'FLARE' IN ECZEMA CARE

Retrieved on: 
Tuesday, April 5, 2022
Human, Bynea, Clinical, Dermatitis, AD, Multimedia, Caregiver, Adult, Seriousness, Atopic dermatitis, Focus, Research, NEA, MBS, Senior, Flare, Health, Disease management, Blueprint, Education, Science, Patient, Disease, Medical device, Pharmaceutical industry, Medicine, Pfizer

NOVATO, Calif., April 5, 2022 /PRNewswire/ -- The National Eczema Association (NEA) announces it has been awarded a competitive grant from Pfizer in the amount of $175K to support its novel research study titled "Atopic Dermatitis Flares – An Understanding and Definition from the Patient Perspective." The grant period commenced in January 2022 with a timeline of 18 months.

Key Points: 
  • NOVATO, Calif., April 5, 2022 /PRNewswire/ -- The National Eczema Association (NEA) announces it has been awarded a competitive grant from Pfizer in the amount of $175K to support its novel research study titled "Atopic Dermatitis Flares An Understanding and Definition from the Patient Perspective."
  • With Pfizer's grant award, NEA will conduct a research study to identify what constitutes a 'flare' from the patient perspective.
  • Wendy Smith Begolka, MBS, Senior Vice President of Scientific and Clinical affairs at NEA, is the principal investigator on the study.
  • Additionally, NEA advances critical eczema research and partners with key stakeholders to ensure the patient voice is represented and valued in education, care and treatment decision-making.

NEA ANNOUNCES 2022 ECZEMA RESEARCH GRANT CYCLE OPENING

Retrieved on: 
Tuesday, March 15, 2022
Quality of life, Seriousness, Education, Health, Patient, NEA, Disease, Multimedia, Human, Pedrá, Bynea, Science, Dermatitis, Caregiver, Life, NIH, Research, CEO, PDT, Atopic dermatitis, Blueprint, Biology, National Institutes of Health, National, Pharmaceutical industry, Medicine

NOVATO, Calif., March 15, 2022 /PRNewswire/ -- The National Eczema Association (NEA) today announced the opening of its 2022 research grant cycle with awards totaling $760,000. NEA continues to increase investment in its research grants, more than doubling the amount awarded in two years, with new grant categories to fund more researchers.

Key Points: 
  • NOVATO, Calif., March 15, 2022 /PRNewswire/ -- The National Eczema Association (NEA) today announced the opening of its 2022 research grant cycle with awards totaling $760,000.
  • As the largest private nonprofit funder of eczema research, NEA has invested over $2.3 million since its first grant was awarded in 2004.
  • Most notably, for every $1 NEA has invested in eczema research, grantees have collectively gone on to obtain an additional $13.14 in subsequent National Institutes of Health (NIH) funding to support further eczema research.
  • The 2022 research grant categories are as follows:
    Impact Research Grant Provides funding support for collaborative research projects to conduct multi-institution innovative eczema research.

NEA Brings Patient Voice To Evaluation Of New Treatments For Atopic Dermatitis (AD)

Retrieved on: 
Tuesday, August 10, 2021
Food and Drug Administration Amendments Act of 2007, Dermatitis, Education, CEO, Health, Caregiver, Atopic dermatitis, Patient, Pain, Food, ICER, Review, Sleep, Itch, Blueprint, NEA, Seriousness, Bynea, Institute for Clinical and Economic Review, Learning, Institute, Research, Goal, Multimedia, AD, FDA, Disease, Human, Neutralizing antibody, Treatment, Pharmaceutical industry

NEA facilitated ICER's engagement with patient experts during the review, with patients and caregivers participating in two learning sessions, and a patient with lifelong AD presenting her eczema journey at the public meeting.

Key Points: 
  • NEA facilitated ICER's engagement with patient experts during the review, with patients and caregivers participating in two learning sessions, and a patient with lifelong AD presenting her eczema journey at the public meeting.
  • "NEA's goal for this process, as with everything we do, is to ensure patients are involved and their important voice is heard," said Julie Block, President and CEO of NEA.
  • Through our patient-reported data and first-person patient accounts, we've aimed to show the diverse and burdensome lived experience of AD and the need for more targeted treatments available to patients."
  • Additionally, NEA advances critical eczema research and partners with key stakeholders to ensure the patient voice is represented and valued in education, care and treatment decision-making.